Fusion proteins with immunoglobulin binding properties, their uses and related methods and compositions are disclosed. The fusion proteins are comprised of an antibody-binding fragment of protein M from Mycoplasma spp. conjugated to a receptor fragment. The receptor fragment is a protein fragment to which a pathogen, a toxin or a cancer cell can specifically bind. The fusion proteins can be used to neutralize or eradicate a wide group of pathogens, toxins or cancer cells.

The present invention relates to methods and engineered microbial hosts useful for treating lignin or a derivative thereof. In some embodiments, the host has one or more exogenous nucleic acid sequences that encode a ligninase (e.g., a laccase and/or a peroxidase).

This invention belongs to the field of preparation of macromolecule sample of various volumes, pertaining to a detergent-mixed dry hydrogel particle and a method of using the particle to mass concentrate the macromolecule liquid sample or to enhance specific activity of the protein liquid sample. After thorough suspension and hydration in a detergent solution, the hydrogel particle is separated from the excess of the detergent solution and dried into the detergent-mixed dry hydrogel particle; upon contacting the macromolecule liquid sample in certain ratio with the dry particle having a pore size of its cross-linked network smaller than the macromolecule to allow absorption and swelling of the hydrogel particle, filter centrifugation or filter conical rotating drum centrifugation is exercised to remove the hydrogel particle whose surface is deprived of water and to collect the concentrate filtrate of the macromolecule mass or the protein sample with enhanced specific activity.

Fusion proteins with immunoglobulin binding properties, their uses and related methods and compositions are disclosed. The fusion proteins are comprised of an antibody-binding fragment of protein M from Mycoplasma spp. conjugated to a receptor fragment. The receptor fragment is a protein fragment to which a pathogen or a toxin can specifically bind. The fusion proteins can be used to neutralize or eradicate a wide group of pathogens or toxins.

The inventive technology relates to systems and methods for enhanced in vivo production, accumulation and modification of cannabinoids. In one embodiment, the invention may include systems and methods for enhanced in vivo biosynthesis of chemically-modified water-soluble cannabinoids in a whole plant, or a cell suspension culture system.

The present disclosure provides recombinant microorganisms and methods for the production of 4-HMF, 2,4-furandimethanol, furan-2,4-dicarbaldehyde, 4-(hydroxymethyl)furoic acid, 2-formylfuran-4-carboxylate, 4-formylfuran-2-carboxylate, and/or 2,4-FDCA from a carbon source. The method provides for engineered microorganisms that express endogenous and/or exogenous nucleic acid molecules that catalyze the conversion of a carbon source into 4-HMF, 2,4-furandimethanol, furan-2,4-dicarbaldehyde, 4-(hydroxymethyl)furoic acid, 2-formylfuran-4-carboxylate, 4-formylfuran-2-carboxylate, and/or 2,4-FDCA. The disclosure further provides methods of producing polymers derived from 4-HMF, 2,4-furandimethanol, furan-2,4-dicarbaldehyde, 4-(hydroxymethyl)furoic acid, 2-formylfuran-4-carboxylate, 4-formylfuran-2-carboxylate, and/or 2,4-FDCA.

The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding said RNA, production host cell lines comprising said RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of said RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.

The present invention relates to the use of a substrate for enhancing the chemiluminescence of one or more luminophores produced in a chemiluminescence reaction, wherein the substrate comprises a solid polymeric carrier with a plurality of depressions separated from one another and that the solid carrier is at least partially coated with a metal.

A method of treating at least one of septicemia, endotoxemia or a bacterial infection in a subject can include administering to the subject a composition containing a therapeutically effective amount of a haloperoxidase. The haloperoxidase can be myeloperoxidase or eosinophil peroxidase. The haloperoxidase can inhibit lipopolysaccharide or Lipid A activity in the subject; as a non-limiting example, the haloperoxidase is not engaged in active haloperoxidase activity, but available for LPS or Lipid A binding and inhibition.

The present invention provides an ascorbate peroxidase mutant MaAPX1.sup.M36K and an application thereof, belonging to the technical field of biotechnology. An amino acid sequence of the mutant MaAPX1.sup.M36K of the present invention is shown in SEQ ID NO. 3. In the present invention, the mutant MaAPX1.sup.M36K reconstruction protein is obtained by the method of prokaryotic expression. It is found that the mutant MaAPX1.sup.M36K improves catalytic efficiency by nearly 5 times, providing a technical reference for further study and application of APX1.